According to Jazz Pharmaceuticals's latest financial reports the company's current revenue (TTM) is $3.83 B. In 2022 the company made a revenue of $3.65 B an increase over the years 2021 revenue that were of $3.09 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $3.83 B | 4.78% |
2022 | $3.65 B | 18.26% |
2021 | $3.09 B | 30.91% |
2020 | $2.36 B | 9.34% |
2019 | $2.16 B | 14.32% |
2018 | $1.89 B | 16.82% |
2017 | $1.61 B | 8.79% |
2016 | $1.48 B | 12.32% |
2015 | $1.32 B | 12.95% |
2014 | $1.17 B | 34.44% |
2013 | $0.87 B | 48.88% |
2012 | $0.58 B | 115.21% |
2011 | $0.27 B | 56.68% |
2010 | $0.17 B | 35.29% |
2009 | $0.12 B | 90.26% |
2008 | $67.51 M | 3.39% |
2007 | $65.3 M | 45.58% |
2006 | $44.85 M | 109.19% |
2005 | $21.44 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Novartis NVS | $51.01 B | 1,230.45% | ๐จ๐ญ Switzerland |
AmerisourceBergen
ABC | $254.42 B | 6,535.67% | ๐บ๐ธ USA |
Endo International
ENDPQ | $2.01 B | -47.54% | ๐ฎ๐ช Ireland |
Teva Pharmaceutical Industries TEVA | $15.84 B | 313.28% | ๐ฎ๐ฑ Israel |